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combined with the use of an inverse optimization method, 
can be used to generate IMPT plans. These plans can be used 
in future dosimetric comparisons with IMRT, the MR Linac and 
conventional IMPT. Finally, it shows the dosimetric feasibility 
of IMPT in a 1.5 T magnetic field.  
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Purpose/Objective: To compare the clinical benefit of robust 
optimized Intensity Modulated Proton Therapy (IMPT) with 
current photon radiotherapy (IMRT) and PTV-based IMPT for 
head and neck cancer (HNC) patients. The clinical benefit is 
quantified in terms of both Normal Tissue Complication 
Probability (NTCP) and target coverage in the case of setup 
and range errors. 
Materials and Methods: For 10 HNC patients, PTV-based IMRT 
(7 fields), robust optimized (minimax) and PTV-based IMPT 
(2, 3, 4, 5 and 7 fields) plans were tested on robustness, 
meaning that at least 98% of the CTVs had to receive ≥ 95% of 
the prescribed dose in 90% of the possible systematic setup 
and range error scenarios. Robust optimized plans differed 
from PTV-based plans in that they target the CTV and 
penalize possible error scenarios, instead of using the static 
isotropic CTV-PTV margin. Perturbed dose distributions of all 
plans were acquired by simulating in total 8060 setup (+/- 
2.5mm) and range error (+/-3%) combinations. Furthermore, 
NTCP models for xerostomia and dysphagia were used to 
estimate the clinical benefit of IMPT versus IMRT.  
Results: The robustness criterion was met in the IMRT and 
minimax IMPT plans in all error scenarios, but for PTV-based 
IMPT plans this was only the case in 4 out of 10 patients. The 
volumes receiving deficient dose were sometimes centrally 
situated in the CTV (Figure), indicating that expansion of the 
CTV-PTV margin would not solve the underdosage. Mean 
doses to the major salivary glands and swallowing related 
organs at risk (OAR) were generally lower with minimax than 
with PTV-based IMPT. Xerostomia and dysphagia NTCP values 
calculated for IMRT plans were reduced by 16.4% (95% CI; 
10.1-22.7%) and 9.9% (95% CI; 4.9-14.9%) with minimax IMPT 
in the 5 patients with the largest NTCP reductions. In the 
other 5 patients the average NTCP reduction was smaller 
(xerostomia: 4.7% (95% CI; 1.0-8.3%) ; dysphagia: 3.0% (95% 
CI; -0.2-6.2%). Increasing the number of fields did not 
contribute to plan robustness, but improved organ sparing. 
Conclusions: The clinical benefit in terms of NTCP of robust 
optimized (minimax) IMPT compared to IMRT is equal or even 
greater than that of PTV-based IMPT in head and neck 
patients. Furthermore, the target coverage of minimax IMPT 
plans in the presence of setup and range errors was 
comparable to that of current photon radiotherapy (IMRT) 
plans.
 
Figure. Dose distributions of IMRT (a,d), PTV-based IMPT (b,e) 
and minimax optimized IMPT plans (c,f) in nominal (a-c) and 
an error scenario (d-f) with a setup error of 
x=0.18;y=0;z=0.18cm and a range error of 3%. Both CTV70 
(blue lines) and CTV54.25 (black lines) are shown in all dose 
distributions.  
   
 
Proffered Papers: RTT 2: Modern treatment planning  
 
 
OC-0164   
Calibration and validation of kV-CBCT in room imaging for 
dose calculation and adaptive radiotherapy 
M. Soumokil- de Bree1, T.S. Rosario2, M.A. Palacios2 
1VUMC and INHOLLAND University, MBRT/ Radiotherapy, 
Haarlem, The Netherlands  
2VUMC, Radiotherapy, Amsterdam, The Netherlands  
 
Purpose/Objective: To investigate the accuracy of dose 
calculation on cone beam CT (CBCT) data sets after HU-RED 
calibration and validation in phantom studies and clinical 
patients. 
Materials and Methods: Calibration of HU-RED curves for kV-
CBCT were generated for three clinical protocols (H&N, 
thorax and pelvis) using a Gammex RMI phantom ® (Gammex 
RMI, Middleton, WI) with human tissue equivalent inserts and 
additional perspex blocks to account for patient scatter. Two 
calibration curves per clinical protocol were defined, one for 
the Varian Truebeam 2.0 and another for the OBI systems 
(Varian Medical Systems Inc., Palo Alto, USA). Differences in 
HU values with respect to the CT-calibration curve were 
evaluated for all the inserts. 
Four radiotherapy plans (breast, prostate, H&N and lung) 
were produced on an anthropomorphic phantom (Alderson) to 
evaluate dose differences on the kV-CBCT with the new 
calibration curves with respect to the CT based dose 
calculation. Dose calculation was performed in Eclipse TPS 
using an anisotropic analytic dose calculation algorithm (AAA, 
Varian Medical Systems Inc.). Dose differences were 
evaluated according to the D2%, D98% and Dmean metrics 
extracted from the DVHs of the plans and g- evaluation (2%, 
1mm) on the three planes at the isocenter for all plans. 
Clinical evaluation was performed on ten patients and dose 
differences were evaluated as in the phantom study. 
Results: HU values on the kV-CBCT calibration curves 
exhibited deviations with respect to the CT-calibration curve 
on the low- (lung) and high-density (bone) inserts. These 
deviations were found to be ca. 250 HU. Differences between 
the Truebeam 2.0 and OBI-system for HU-RED curve were 
ca.14 %. Radiotherapy plans calculated on the 
anthropomorphic phantom showed very good agreement with 
the CT-based calculated plans (Table 1, Figure 1).  
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Only few structures for some specific metrics, such as Dmean 
rectum and D98% parotid glands exhibited deviations larger 
than 3%. g-analysis (2%, 1mm) on the three planes at 
isocenter showed a pass-rate higher than 98% for all cases. 
Clinical evaluation in ten patients showed very good 
agreement with the dose calculation on the CT as expressed 
by the D2%, D98% and Dmean of the delineated structures. 
Several drawbacks were also found: the limited FOV of the 
kV-CBCT, which impairs the dose evaluation of those 
structures in its vicinity and the difference in beam profile of 
the kV-CBCT with respect to the CT, reducing the accuracy of 
the dose estimation at nearby the surface of the patient.  
Conclusions: The generation of three kV-CBCT specific HU-
RED curves for the pelvis, thorax and H&N cases resulted in 
accurate dose calculation on kV-CBCT images. Very good 
agreement was found with the CT-based dose calculated 
plans according to DVH dose parameters and g-evaluation. 
Limitations of the kV-CBCT warrant some caution when 
evaluating dose differences for adaptive radiotherapy. 
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Purpose/Objective: Given the complexity of modulated 
fields, the validity of the traditional central axis FSD 
measurement is now being questioned. This study aims to 
quantify the impact a change in patient body contour, away 
from the central axis, has on target dose when treating dose 
escalated image guided IMRT and VMAT for definitive and 
post prostatectomy prostate cancer. 
Materials and Methods: A total of 39 patients, 22 definitive 
and 17 post prostatectomy, were included in this 
retrospective dosimetric study. Both IMRT and VMAT plans 
were calculated with a prescription dose of 80Gy and 64Gy 
for definitive and post surgical cases respectively. The 
treatment plan was applied to each of the patients’ weekly 
cone beam scans and all plans were recalculated with the 
homogeneity correction inactivated allowing for direct 
dosimetric comparison. FSDs were recorded for each IMRT 
field on each scan. The CTV D100, PTV D98, PTV D95, PTV 
D2, PTV mean and PTV median doses along with the 98% and 
95% conformity indices and homogeneity index were recorded 
for all 712 plans analyzed. Statistical analysis included 
repeated measures ANOVA and Freidman’s tests for the 
whole treatment course. Individual CBCT dependant variables 
were further analysed using paired samples T tests and 
Wilcoxon Signed Rank tests. 
Results: A total of 712 plans were created, 6408 dependant 
variables analysed and 2502 FSD measurements recorded. Of 
the FSD measurements taken from CBCTs for the IMRT plans, 
96.3% and 100% were within 1cm from the planned value for 
definitive and post prostatectomy patients respectively. For 
the definitive cohort, an increase in dose was observed 
across each metric measured (p<0.05). Subsequent analysis 
revealed 83.3% of individual measurements from CBCTs were 
significantly different (p<0.05) from the original planned 
value. For the post prostatectomy cohort only the IMRT 
homogeneity index (p=0.000) and the VMAT PTV D98 
(p=0.009), 98% (p=0.006) and 95% (p=0.002) conformity 
indices and homogeneity index (p=0.022) were significantly 
different from the planned value based on measures of 
variance. Analysis of the individual CBCTs for this group 
revealed 88% and 71.4% of endpoints measured were 
statistically similar to the original plan for IMRT and VMAT 
respectively. 
Conclusions: IMRT and VMAT beams are complex in nature. 
The endpoints analysed in this research indicate statistical 
differences to target doses despite the FSD measurements 
being within the nominal tolerance. The traditional central 
axis measurement is an insufficient indicator for dosimetric 
variation with modulated beams. As such a volumetric 
approach to contour variation, through the use of CBCT, is 
essential when treating with IMRT or VMAT. 
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Purpose/Objective: The use of IMRT for cervical cancer can 
significantly reduce dose to normal tissue. However, there is 
substantial uterine motion during treatment resulting from 
variation in bladder and rectal filling and this risk of a 
geographical miss has limited the implementation of IMRT. A 
population based CTV-PTV margin requires 15-30mm to 
ensure coverage throughout treatment but this encompasses 
large volumes of normal tissue. Daily online imaging with an 
adaptive approach may reduce margins but is very resource 
intensive. IMRT can still be safely introduced if internal 
motion throughout treatment can be accurately predicted to 
individualise volumes. 
Our aim was to assess whether variable bladder filling scans 
can be used to predict uterine position during treatment and 
compare methods for generating the final PTV. 
Materials and Methods: A retrospective analysis was 
performed of 11 patients treated with primary chemo-
radiotherapy for cervical carcinoma. Patients underwent 
‘bladder full’ radiotherapy planning scans and ‘bladder 
empty’ pre-treatment diagnostic imaging, with images co-
registered on the treatment planning software. The uterus 
and cervix were contoured on the planning scan to generate 
the CTVuterus and an isotropic 15mm expansion made to 
generate the unmodified PTVuterus. A manually modified PTV 
was made by the clinician taking into account the change in 
uterine position between scans. CBCT verification was 
performed weekly during treatment. The unmodified and 
